Abstract: Crystalline forms of N-{3-[(1S)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]-phenyl}-5-methylpyridine-3-carboxamide are provided. Pharmaceutical compositions and dosage forms containing the crystal forms are also provided, including related methods for modulating kinases generally, and specifically to treatment of PAH.
Type:
Grant
Filed:
May 6, 2022
Date of Patent:
August 11, 2026
Assignee:
GB002, Inc.
Inventors:
Marcus Schestopol, Beili Zhang, David Paisner, Nicole White, Esmir Gunic
© 2026 Justia
